These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22427735)

  • 1. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
    Kreutz RP; Nystrom P; Kreutz Y; Miao J; Desta Z; Breall JA; Li L; Chiang C; Kovacs R; Flockhart DA; Jin Y
    Clin Pharmacol; 2012; 4():13-20. PubMed ID: 22427735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study.
    Tanaka K; Matsumoto S; Ainiding G; Nakahara I; Nishi H; Hashimoto T; Ohta T; Sadamasa N; Ishibashi R; Gomi M; Saka M; Miyata H; Watanabe S; Okata T; Sonoda K; Koge J; Iinuma KM; Furuta K; Nagata I; Matsuo K; Matsushita T; Isobe N; Yamasaki R; Kira JI
    PLoS One; 2021; 16(8):e0254067. PubMed ID: 34351918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
    Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
    Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.
    Chen Y; Huang X; Tang Y; Xie Y; Zhang Y
    Int J Clin Exp Med; 2015; 8(6):9266-74. PubMed ID: 26309584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α2A-Adrenergic receptor polymorphism potentiates platelet reactivity in patients with stable coronary artery disease carrying the cytochrome P450 2C19*2 genetic variant.
    Peace AJ; Mangiacapra F; Bailleul E; Delrue L; Dierickx K; Conte M; Puymirat E; Fraeymans AL; Meeus P; Bartunek J; Volpe M; Barbato E
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1314-9. PubMed ID: 24723553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
    Dai ZL; Chen H; Wu XY
    Zhong Xi Yi Jie He Xue Bao; 2012 Jun; 10(6):647-54. PubMed ID: 22704413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.